Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Seeking Alpha
Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman of the Board & CEO Christopher Hite - Vice Chairman & Executive VP Marshall Urist - Executive Vice President of Research & Investments Terrance Coyne - Executive VP & CFO Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Michael Nedelcovych - TD Cowen, Research Division Terence Flynn - Morgan Stanley, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Ashwani Verma - UBS Investment Bank, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Dina Ramadane - BofA Securities, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to the Royalty Pharma Fourth Quarter Earnings Conference Call. I would like now to turn the confere
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions [Seeking Alpha]Seeking Alpha
- Royalty Pharma Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma reports Q4 results [Seeking Alpha]Seeking Alpha
RPRX
Sec Filings
- 2/11/26 - Form 10-K
- 2/11/26 - Form 8-K
- 2/4/26 - Form 4
- RPRX's page on the SEC website